Evotec SE preliminary fiscal year 2022 results: "Ahead of the curve"– very...
Evotec SE today reported preliminary financial results and corporate updates for the fiscal year ended 31 December 2022.
View ArticleEvotec and Bristol Myers Squibb extend and expand strategic neurodegeneration...
Evotec SE announced today that the Company has extended and expanded its strategic neurodegeneration partnership with Bristol Myers Squibb, originally signed in 2016. The initial partnership proved...
View ArticleAd hoc: Evotec and Bristol Myers Squibb expand strategic neurodegeneration...
Evotec SE announces today that the Company has extended and expanded its strategic partnership with Bristol Myers Squibb (NYSE:BMY) in neurodegeneration, originally signed in 2016. Aim of the 8-year...
View ArticleAd hoc: Cyber Attack on Evotec
Evotec SE announces that on 06 April, 2023 a cyber attack occurred on Evotec‘s IT systems. As a result, the systems were shut down proactively and disconnected from the Internet to secure from data...
View ArticleEvotec SE provides update on cyber attack
Evotec SE today announced an update on the cyber attack that was detected on 06 April, 2023. Evotec noticed unusual activity in one of the Company’s IT systems and immediately took steps to maintain IT...
View ArticleCEO-Letter: #researchneverstops cannot be stopped by cyber-attacks
Dear Friends of Evotec, We detected a cyber-attack on 6 April. I write you today from my temporary E-Mail werner.lanthaler@evotec.eu, which might appear as a sign that we are “back”, but in fact we...
View ArticleEvotec-Partner Tubulis Announces Strategic License Agreement with Bristol...
Evotec-partner Tubulis and Bristol Myers Squibb (NYSE: BMY) today announced that they have entered into a strategic license agreement to develop differentiated antibody-drug conjugates ("ADCs").
View ArticleEvotec-Sernova Partnership: Successful Results Presented at the 4th...
Evotec's partner Sernova, a clinical-stage company and leader in cell therapeutics, today announced the presentation of preclinical data supporting the anticipated 2024 IND submission and planned Phase...
View ArticleCyprotex US celebrates Grand Opening of new facility in Framingham, MA
Evotec SE announced today that Cyprotex US celebrated the grand opening of its new state-of-the-art facility in Framingham, MA, today. Evotec announced the relocation of Cyprotex US, LLC to the new...
View ArticleEvotec SE: Statement regarding unscheduled change in Qontigo indices
Evotec has been informed that Qontigo, the index operator of Deutsche Boerse, has decided to remove Evotec from MDAX and TecDAX effective 09 May. The reason for the unexpected index change was...
View ArticlePartnership with Sandoz
Just - Evotec Biologics launches partnership with Sandoz for biosimilars development and commercial manufacturing.
View ArticleAd hoc: Just – Evotec Biologics enters strategic biosimilars partnership...
Evotec SE announces that Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc., has entered a multi-year, long-term tech partnership with Sandoz for the immediate development and subsequent...
View ArticleJust – Evotec Biologics launches tech partnership for biosimilars...
Evotec SE and Sandoz AG, a division of Novartis (NASDAQ: NVS) today announced that Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc., launched a multi-year, long-term tech partnership...
View ArticleEvotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023
Evotec SE today published its Annual Report for the fiscal year 2022, as well as the qualitative Quarterly Statement for the first quarter of 2023.
View ArticleEvotec`s PanHunter Receives Honorable Mention World Changing Ideas Awards
PanHunter receives an honorable mention is the software category of Fast Company's 2023 World Changing Ideas Awards.
View ArticlePublication of Sustainability Report 2022
Evotec has published its Sustainability Report 2022. In reference to the GRI standards and for the first time partially audited, it is a testament to our progress made in shaping a resilient and...
View ArticleEvotec SE: Accelerating drug discovery with screening technologies of ...
Evotec SE today announced that new high-throughput screening (“HTS”) facilities at the Company’s headquarters in Hamburg, as well as additional equipment for investigating the safety and efficacy of...
View ArticleEvotec receives grant from Open Philanthropy...
Evotec SE today announced that the Company has received a $ 1.7 m grant from Open Philanthropy, a philanthropic funder prioritising global health and wellbeing. Under the grant, Evotec aims to discover...
View ArticleEvotec presents sustainability strategy
Evotec SE today presents an update on the Company’s sustainability strategy and shares details on its ESG (Environmental, Social and Governance) performance towards strengthening its competitiveness...
View ArticleEvotec SE to resume dual listing in MDAX and TecDAX
Evotec SE will resume its dual listing in the German stock indices MDAX and TecDAX, following the quarterly index review of the DAX index family through Qontigo, the index operator of Deutsche Börse....
View Article